Protalix BioTherapeutics (PLX) Corporate presentation summary

Leadership and governance

• Executive team brings decades of experience in pharma, R&D, business development, and capital markets.

• Board of Directors includes industry veterans with backgrounds in biotech, pharma, and finance.

Commercial portfolio and partnerships

• Two approved enzyme replacement therapies: Elfabrio for Fabry disease and Elelyso for Gaucher disease, generating revenue in multiple markets.

• Global partnerships with Chiesi, Pfizer, and Fiocruz support commercialization and market expansion.

• Elfabrio approved in US, EU, and other markets; Elelyso approved in 23 markets.

• Significant milestone payments and royalties from partners, with Elfabrio poised for 15–20% global market share.

Financial performance and outlook

• Achieved profitability with $22.1M net income in H1 2026 and $53.6M total revenues YTD, driven by Elfabrio sales and milestone payments.

• Cash position of $40.7M as of June 30, 2026, with no debt or warrants and 80.6M shares outstanding.

• Well-capitalized to support ongoing operations and pipeline development.